BrainStorm Cell Therapeutics Inc. (BCLI) stock
BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.77−0.01 (-1.17%)
Close on Oct 19, 2026Market cap $8.50MP/E –Yield –
BrainStorm Cell Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
BrainStorm Cell Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$4.06M. For fiscal 2025 it was -$6.98M. The highest annual figure on record is -$2.07M in fiscal 2010.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.98M | – |
| FY2024 | Dec 31, 2024 | -$9.09M | – |
| FY2023 | Dec 31, 2023 | -$20.46M | – |
| FY2022 | Dec 31, 2022 | -$19.32M | – |
| FY2021 | Dec 31, 2021 | -$26.27M | – |
| FY2020 | Dec 31, 2020 | -$35.19M | – |
| FY2019 | Dec 31, 2019 | -$11.25M | – |
| FY2018 | Dec 31, 2018 | -$12.39M | – |
| FY2017 | Dec 31, 2017 | -$2.36M | – |
| FY2016 | Dec 31, 2016 | -$5.86M | – |
| FY2015 | Dec 31, 2015 | -$7.41M | – |
| FY2014 | Dec 31, 2014 | -$4.49M | – |
| FY2013 | Dec 31, 2013 | -$4.05M | – |
| FY2012 | Dec 31, 2012 | -$2.94M | – |
| FY2011 | Dec 31, 2011 | -$2.22M | – |
| FY2010 | Dec 31, 2010 | -$2.07M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$895.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.32M | – |
| Q4 FY2025 | Dec 31, 2025 | -$740.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.10M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.63M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.05M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.30M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.68M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.06M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.41M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.78M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.99M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.65M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.85M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.13M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.69M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.51M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.46M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.33M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.97M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.58M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.92M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.66M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.03M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.28M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.63M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.51M | -6478.2% |
| Q1 FY2019 | Mar 31, 2019 | -$835.00K | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.72M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.59M | -271.6% |
| Q2 FY2018 | Jun 30, 2018 | $55.00K | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.13M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.94M | – |
| Q3 FY2017 | Sep 30, 2017 | $3.84M | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.63M | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.64M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.20M | – |
| Q3 FY2016 | Sep 30, 2016 | -$275.00K | – |
See a number that looks wrong?